Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements (Detail)

v3.21.2
Research and Development Agreements - Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue Recognition [Line Items]          
Total research and development revenue, related party $ 2,379   $ 4,298 $ 20,733 $ 12,138
Takeda Development Agreement          
Revenue Recognition [Line Items]          
Total research and development revenue, related party   $ 12,900      
Millennium Pharmaceuticals Inc          
Revenue Recognition [Line Items]          
Total research and development revenue, related party 0   1,566 13,136 4,962
Millennium Pharmaceuticals Inc | Takeda Development Agreement          
Revenue Recognition [Line Items]          
Total research and development revenue, related party 0   86 13,114 307
Millennium Pharmaceuticals Inc | Takeda Multi Target Agreement          
Revenue Recognition [Line Items]          
Total research and development revenue, related party $ 0   $ 1,480 $ 22 $ 4,655